| Assessment Status | Rapid Review Complete |
| HTA ID | 25034b |
| Drug | Selpercatinib |
| Brand | Retsevmo® |
| Indication | Selpercatinib (Retsevmo®) is indicated in adults and adolescents 12 years and older with advanced RET fusion-positive thyroid cancer who are radioactive iodine-refractory (if radioactive iodine is appropriate). |
| Assessment Process | |
| Rapid review commissioned | 15/05/2025 |
| Rapid review completed | 01/07/2025 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of selpercatinib compared with the current standard of care. |
| Full HTA commissioned by the HSE | 11/06/2025 |
| Pre-submission consultation with Applicant | 06/08/2025 |
The company has not submitted a HTA dossier to the NCPE; therefore the cost-effectiveness of the technology could not be proven.
Further information on the status of this application may be found here.